Stock MDNA MEDICENNA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Medicenna Therapeutics Corp. Stock

Equities

MDNA

CA58490H1073

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 03:59:59 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.55 CAD +1.31% Intraday chart for Medicenna Therapeutics Corp. -15.76% +269.05%
Apr. 16 Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Apr. 10 Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR MT

Financials

Sales 2024 * - Sales 2025 * 583K 426K Capitalization 108M 78.86M
Net income 2024 * -16M -11.69M Net income 2025 * -19M -13.88M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 185 x
P/E ratio 2024 *
-6.6 x
P/E ratio 2025 *
-5.96 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.73%
More Fundamentals * Assessed data

Chart Medicenna Therapeutics Corp.

Dynamic Chart

Latest news about Medicenna Therapeutics Corp.

Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024 MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting CI
Medicenna Reports Q3 Net Loss $5.0 Million MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022 MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors CI
More news

Latest transcript on Medicenna Therapeutics Corp.

Logo Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
More transcripts

Analyst Recommendations on Medicenna Therapeutics Corp.

Oppenheimer Adjusts Medicenna Therapeutics Price Target to $3 From $8, Maintains Outperform Rating MT
HC Wainwright Reiterates Medicenna Therapeutics at Buy With $2.50 Price Target MT
HC Wainwright Adjusts Price Target on Medicenna Therapeutics to $2.50 From $4, Maintains Buy Rating MT
HC Wainwright Adjusts Medicenna Therapeutics' Price Target to $4 From $5, Keeps Buy Rating MT
Oppenheimer Adjusts Medicenna Therapeutics Price Target to $8 From $10, Maintains Outperform Rating MT
More recommendations

Press releases Medicenna Therapeutics Corp.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study AQ
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research AQ
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) AQ
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) AQ
Medicenna to Present at the 2024 Bloom Burton and Co. Healthcare Investor Conference AQ
More press releases

Quotes and Performance

1 day+1.31%
1 week-15.76%
Current month-16.67%
1 month-1.90%
3 months+240.66%
6 months+307.89%
Current year+269.05%
More quotes

Highs and lows

1 week
1.50
Extreme 1.5
1.77
1 month
1.40
Extreme 1.4
2.10
Current year
0.40
Extreme 0.4
2.10
1 year
0.22
Extreme 0.215
2.10
3 years
0.22
Extreme 0.215
4.90
5 years
0.22
Extreme 0.215
7.25
10 years
0.22
Extreme 0.215
7.25
More quotes

Managers and Directors - Medicenna Therapeutics Corp.

Managers TitleAgeSince
Rosemina Merchant FOU
 Founder - 11-09-30
Fahar Merchant CEO
 Chief Executive Officer - 15-02-01
David Hyman DFI
 Director of Finance/CFO - Feb. 13
Members of the board TitleAgeSince
Karen Dawes BRD
 Director/Board Member 72 19-09-23
Albert Beraldo BRD
 Director/Board Member - 16-11-21
Fahar Merchant CEO
 Chief Executive Officer - 15-02-01
More insiders

Quotes

Date Price Change Volume
24-04-23 1.55 +1.31% 70,982
24-04-22 1.53 -6.71% 162,794
24-04-19 1.64 -1.80% 81,864
24-04-18 1.67 -3.47% 88,949
24-04-17 1.73 -5.98% 158,701

Delayed Quote Toronto S.E., April 23, 2024 at 03:59 pm EDT

More quotes

Company Profile

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Sector
Biotechnology & Medical Research
Calendar
2024-06-25 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.55 CAD
Average target price
9 CAD
Spread / Average Target
+480.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MEDICENNA THERAPEUTICS CORP. Stock Medicenna Therapeutics Corp.
+269.05% 78.95M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+48.37% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MDNA Stock